Strategic Focus Atia Vision targets a high-impact ophthalmology niche with a modular presbyopia-correcting IOL, presenting a clear opportunity to align with surgeons and hospitals seeking advanced vision restoration solutions and differentiated patient outcomes.

Clinical Validation Recent positive 36-month data and first-in-human results showcased at ASCRS indicate growing clinical credibility, creating openings for partnerships with KOLs, early adopters, and trial expansion in U.S. clinical sites.

Regulatory Progress FDA approval to begin US clinical trials for the OmniVu Lens System signals a near-term regulatory milestone, enabling targeted outreach to clinical centers, study coordinators, and CROs involved in ophthalmic trials.

Funding & Growth Significant funding history (Series E and overall funding) and a revenue range in the low millions suggest capacity for co-development, pilot programs, or strategic partnerships with clinics and distributors to accelerate market entry.

Partnership Readiness As a Shifamed portfolio company with an innovation-first approach, Atia Vision is positioned to engage medical device distributors, eye-care networks, and hospital systems seeking differentiated IOL solutions and accelerated product-to-market timelines.